Overview

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Status:
Recruiting
Trial end date:
2023-04-23
Target enrollment:
Participant gender:
Summary
To evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Erenumab